Zacks Investment Research upgraded shares of Swedish Orphan Biovitrum (OTCMKTS:SWTUY) from a hold rating to a buy rating in a research report sent to investors on Friday morning. The firm currently has $21.00 target price on the stock.
According to Zacks, “Swedish Orphan Biovitrum AB is a biopharmaceutical company which develops and makes drugs for patients with rare diseases. Its product portfolio primarily includes Kineret within the inflammation therapeutic area, Orfadin, Ammonaps and Ammonul within the genetics and metabolic therapeutic which are in clinical trial stage. Swedish Orphan Biovitrum AB is headquartered in Stockholm, Sweden. “
OTCMKTS:SWTUY opened at $18.50 on Friday. Swedish Orphan Biovitrum has a one year low of $12.55 and a one year high of $18.50.
WARNING: This piece was originally reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://dakotafinancialnews.com/2018/04/14/swedish-orphan-biovitrum-swtuy-upgraded-to-buy-at-zacks-investment-research.html.
Swedish Orphan Biovitrum AB (publ), an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Sweden and internationally. Its core products include Kineret for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease; Orfadin for the treatment of hereditary tyrosinaemia type 1 genetic disorder; and Xiapex for the treatment of Dupuytren's contracture and Peyronie's disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Swedish Orphan Biovitrum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum and related companies with MarketBeat.com's FREE daily email newsletter.